Vesalius Biocapital, a venture capital firm specializing in the life sciences sector, recently announced the successful initial closing of its fourth fund, Vesalius Biocapital IV. This fund has secured commitments exceeding €95 million ($103.7 million) and attracted prominent investors such as the European Investment Fund (EIF). Focused on investing in innovative European life science companies in the fields of drug development and digital health, Vesalius Biocapital IV aims to create a portfolio of 10 to 15 leading companies within these domains.
With a successful track record spanning 16 years, Vesalius Biocapital has raised over €270 million ($294.8 million) across its three previous funds. The firm has been instrumental in supporting groundbreaking companies, making more than 30 investments to date. They have played significant roles as lead or co-lead investors, achieving notable exits through trade sales and initial public offerings (IPOs). Noteworthy examples include Forendo, acquired by Organon; Sword Health, sold to a consortium of private equity investors; Apitope, acquired by Chinese company Worg Pharma; and Ogeda, acquired by Astellas Pharma.
Expressing enthusiasm about the fund’s success, Stéphane Verdood, managing partner at Vesalius Biocapital IV, stated, “Our strong track record has positioned us well to attract top-tier investors like the EIF to Vesalius Biocapital IV. Additionally, the support from many investors who have previously backed our funds validates our investment approach and strategy. We are currently experiencing an exciting era in healthcare, with the convergence of science, technology, and medicine. Our investors endorse our strategy of investing in companies that develop innovative first-in-class products and technologies.”
Marjut Falkstedt, CEO of the European Investment Fund, emphasized the importance of targeted investments for the development of new therapies and digital health solutions. Falkstedt commented, “The healthcare sector is undergoing a revolution with these innovations, but they require dedicated and focused investment. The EIF is delighted to partner with Vesalius for their fourth fund, leveraging their strong track record in the sector. The fund aims to direct investments towards underserved areas in the innovation landscape, particularly in southern Europe.”
Vesalius Biocapital IV aims to reach a target size of €150 million ($163.7 million) and will accept new investors on a rolling closing basis until the final closing in 2024.
